IVT PCV-25 not checked

Inventprise Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pneumococcal Disease, Invasive
Main trialPhase 2
“Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants”In the company’s words, NCT06790290 on ClinicalTrials.gov
Other names
Formulation B · Formulation C · Formulation D

Other drugs for Pneumococcal Disease, Invasive

All 17 drugs for Pneumococcal Disease, Invasive

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 3 Apr 2025 Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2Completed 24 May 2024 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Phase 1Completed 31 Jul 2023 Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IVT PCV-25

Following is part of Solo: you see every change to IVT PCV-25 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in